Cargando…

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Detalles Bibliográficos
Autores principales:	Weycker, Derek, Li, Xiaoyan, Wygant, Gail DeVecchis, Lee, Theodore, Hamilton, Melissa, Luo, Xuemei, Vo, Lien, Mardekian, Jack, Pan, Xianying, Burns, Leah, Atwood, Mark, Hanau, Ahuva, Cohen, Alexander T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548234/ https://www.ncbi.nlm.nih.gov/pubmed/31986533 http://dx.doi.org/10.1055/s-0039-3400530

Ejemplares similares

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis
por: Cohen, Alexander, et al.
Publicado: (2021)

Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States
por: Deitelzweig, Steven, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice: A propensity-matched analysis of 76,940 patients
por: Li, Xiaoyan, et al.
Publicado: (2017)

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
por: Li, Xiaoyan, et al.
Publicado: (2018)

Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database
por: Guo, Jennifer D., et al.
Publicado: (2020)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial
por: Liu, Xianchen, et al.
Publicado: (2015)

Safety and effectiveness of apixaban compared to warfarin in dialysis patients
por: Reed, Daniel, et al.
Publicado: (2018)

Apixaban/heparin/warfarin: Treatment failure: case report
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

1514. Mortality and Readmission in Adults during the First Year Following Hospitalization for Community-Acquired Pneumonia in the US
por: Sato, Reiko, et al.
Publicado: (2020)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2019)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

A comparison between warfarin and apixaban: A patient's perspective
por: Althemery, Abdullah U., et al.
Publicado: (2020)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

1510. Infant Pneumonia and Subsequent Risk of Chronic Respiratory Disorders
por: Pelton, Stephen I, et al.
Publicado: (2020)

Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report
por: Koga, Masashi, et al.
Publicado: (2018)

Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study
por: Ellenbogen, Michael I., et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients
por: Alotaibi, Sultan N, et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia
por: Al Yami, Majed S, et al.
Publicado: (2021)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tl4jhned9a5ti7e84ftr101jns